Dataset from A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009326
下载链接
链接失效反馈官方服务：
资源简介：
Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel
group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added
to titrated basal insulin glargine with or without metformin to placebo added to titrated
basal insulin glargine with or without metformin in patients with type 2 diabetes mellitus
(T2DM). Eligible patients will be randomized at Visit 5 (Day 1) to receive either EQW added
to titrated basal insulin glargine, with or without metformin ≥1500 mg/day, or placebo added
to titrated basal insulin glargine, with or without metformin ≥1500 mg/day, during the
28-week treatment period.
创建时间：
2025-07-06
